Nomination Committee 2019
According to the principles for the appointment of the Nomination Committee in Oncopeptides AB (publ) adopted at the annual general meeting held on 17 May 2018, the Nomination Committee for the annual general meeting 2019 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of 28 September, along with the Chairman of the Board of Directors.
The composition of the Nomination Committee has now been established, and Oncopeptides today announced that the Nomination Committee in respect of the annual general meeting 2019 consists of the following persons who together represent approximately 55 percent of the number of shares and votes in the company based on the last known shareholder information at end September.
- Staffan Lindstrand, appointed by HealthCap VI L.P.
- David Sonnek, appointed by Stiftelsen Industrifonden
- Max Mitteregger, appointed by GLADIATOR
- Per Wold-Olsen, the Chairman of the Board
The Nomination Committee’s proposals will be presented in the Notice to the annual general meeting 2019 and on Oncopeptides’ web site, www.oncopeptides.com.
Shareholders who wishes to submit proposals to the Nomination Committee can do so by sending an e-mail to email@example.com (subject “Nomination Committee”) or by letter posted to Oncopeptides AB (publ), Attn: Oncopeptides Nomination Committee, Luntmakargatan 46, SE-111 37 Stockholm, Sweden.
A proposal must reach the nomination committee no later than by April 2nd to be included in the notice to attend and the agenda for the annual general meeting.
For further information, please contact:
Staffan Lindstrand, Chairman of the Nomination Committee of Oncopeptides AB (publ), appointed by HealthCap VI L.P. E-mail: firstname.lastname@example.org